P

Pharmena SA
WSE:PHR

Watchlist Manager
Pharmena SA
WSE:PHR
Watchlist
Price: 2.65 PLN 1.92% Market Closed
Market Cap: 29.5m PLN
Section:
 

Relative Value

The Relative Value of one PHR stock under the Base Case scenario is hidden PLN. Compared to the current market price of 2.65 PLN, Pharmena SA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PHR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

23.2
P/S
P/S
Price to Sales
23.2
vs History
42
vs Industry
1
Median 3Y
62.1
Median 5Y
11.7
Industry
1.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
62
Median 3Y
-21.4
Median 5Y
-19.2
Industry
17.8
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
64
Median 3Y
-4.5
Median 5Y
-15.3
Industry
11.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
52
Median 3Y
-3.2
Median 5Y
-13.6
Industry
15.6
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
39
vs Industry
13
Median 3Y
3.3
Median 5Y
-9.6
Industry
1.5
More Details
16
EV/S
EV/S
Enterprise Value to Sales
16
vs History
42
vs Industry
1
Median 3Y
44.6
Median 5Y
12.3
Industry
1.2
More Details
18.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
18.9
vs History
47
vs Industry
0
Median 3Y
64.1
Median 5Y
21.7
Industry
4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
0
Median 3Y
-10.3
Median 5Y
-19
Industry
10.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
64
Median 3Y
-11.7
Median 5Y
-18.5
Industry
13.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
64
Median 3Y
-3.7
Median 5Y
-11.8
Industry
12.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
55
Median 3Y
-3.7
Median 5Y
-10.8
Industry
15.7
More Details
7.6
EV/IC
EV/IC
Enterprise Value to IC
7.6
vs History
93
vs Industry
1
Median 3Y
26
Median 5Y
22.3
Industry
1.2
More Details

Multiples Across Competitors

PHR Competitors Multiples
Pharmena SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Pharmena SA
WSE:PHR
29.5m PLN 23.2 -14.8 -6.9 -6.7
FR
L'Oreal SA
PAR:OR
194.4B EUR 4.4 31.8 18.4 22.4
UK
Unilever PLC
LSE:ULVR
118.2B GBP 2.2 23.6 184.5 214.3
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.5T INR 8.6 50.7 36.8 40.7
UK
HALEON PLC
LSE:HLN
33.3B GBP 3 23.1 13.9 15.8
US
Estee Lauder Companies Inc
NYSE:EL
38.5B USD 2.7 -41.4 20.9 34.6
DE
Beiersdorf AG
XETRA:BEI
20.4B EUR 2.1 23.2 11.4 14.6
JP
Kao Corp
TSE:4452
2.9T JPY 1.7 23.6 11.2 17.3
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.3T INR 8.5 69.4 43.1 47.2
IN
Dabur India Ltd
NSE:DABUR
926.2B INR 7.2 51.2 38.4 47.6
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD 855.7 -4 624.4 -6 373.4 -6 360.4
P/E Multiple
Earnings Growth PEG
PL
P
Pharmena SA
WSE:PHR
Average P/E: 37.1
Negative Multiple: -14.8 		N/A N/A
FR
L'Oreal SA
PAR:OR
31.8
8%
4
UK
Unilever PLC
LSE:ULVR
23.6
15%
1.6
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
50.7
8%
6.3
UK
HALEON PLC
LSE:HLN
23.1
12%
1.9
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -41.4 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
23.2
8%
2.9
JP
Kao Corp
TSE:4452
23.6
13%
1.8
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
69.4
19%
3.7
IN
Dabur India Ltd
NSE:DABUR
51.2
12%
4.3
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
P
Pharmena SA
WSE:PHR
Average EV/EBITDA: 42.1
Negative Multiple: -6.9 		N/A N/A
FR
L'Oreal SA
PAR:OR
18.4
5%
3.7
UK
Unilever PLC
LSE:ULVR
184.5
1%
184.5
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
36.8
8%
4.6
UK
HALEON PLC
LSE:HLN
13.9
4%
3.5
US
Estee Lauder Companies Inc
NYSE:EL
20.9
15%
1.4
DE
Beiersdorf AG
XETRA:BEI
11.4
-1%
N/A
JP
Kao Corp
TSE:4452
11.2
8%
1.4
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
43.1
13%
3.3
IN
Dabur India Ltd
NSE:DABUR
38.4
11%
3.5
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -6 373.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
P
Pharmena SA
WSE:PHR
Average EV/EBIT: 50.5
Negative Multiple: -6.7 		N/A N/A
FR
L'Oreal SA
PAR:OR
22.4
6%
3.7
UK
Unilever PLC
LSE:ULVR
214.3
1%
214.3
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
40.7
9%
4.5
UK
HALEON PLC
LSE:HLN
15.8
4%
4
US
Estee Lauder Companies Inc
NYSE:EL
34.6
25%
1.4
DE
Beiersdorf AG
XETRA:BEI
14.6
-2%
N/A
JP
Kao Corp
TSE:4452
17.3
N/A N/A
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
47.2
13%
3.6
IN
Dabur India Ltd
NSE:DABUR
47.6
11%
4.3
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -6 360.4 N/A N/A

See Also

Summary
PHR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHR stock valuation using valuation multiples.
Wall Street Estimates
PHR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.